IP Library Granted Patent US 10,087,489
Granted Patent B2
US 10,087,489 · App. 15/276,131 · Granted Oct 2, 2018

Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

Inventors: Steven Buechler (Granger, IN); Amanda B. Hummon (Granger, IN)
Assignee: The University of Notre Dame
C12Q1/6886C12N5/0693C12Q1/686G01N33/57419G01N33/57484C12Q2600/106C12Q2600/118G01N2800/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,087,489
App. No.
15/276,131
Granted
Oct 2, 2018
Kind
B2
Abstract

Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed.

Claims (12)

1. A panel of probes for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of:

CDX2, FAM69A, FAM84A, ITPRIP, ITGA3, RAB3B, SMAD3, PCSKS, and MMP28.

2. A panel of probes for indicating a 5-year right-side colon cancer (RCC) relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of:

CDX2, FAM69A, FAM84A, ITPRIP, ITGA3, RAB3B, SMAD3, PCSK5, MMP28,CDKN2B, GADD45A, and CCND1.

3. A panel of probes for indicating a 5-year RCC relapse probability of RCC in a post-surgery human RCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of CDX2 and FAM69A.

4. The panel of probes of claim 1 , 2 or 3 , wherein the detectably labeled single-stranded polynucleotides are immobilized to a solid surface.

5. The panel of probes of claim 1 , 2 or 3 wherein the detectable label is a fluorescent label or a radiolabel.

6. The panel of probes of claim 4 , wherein the solid surface is nylon, plastic, silicon, or ceramic.

7. The panel of probes of claim 4 wherein the solid surface is a silicon wafer.

8. The panel of probes of claim 4 wherein the solid surface is a glass.

9. The panel of probes of claim 8 wherein the glass is a glass slide or a glass chip.

10. The panel of probes of claim 4 wherein the probes are fixed to the solid surface by a covalent bond.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2018
From: BUECHLER, STEVEN; HUMMON, AMANDA
To: THE UNIVERSITY OF NOTRE DAME
Reel/Frame 046729/0500 →
Continuity (5)
Division 14454552 · Aug 7, 2014
Division 13332071 · Dec 20, 2011
Provisional Application 61462592 · Feb 4, 2011
Provisional Application 61459864 · Dec 20, 2010
Related Publication 20170283877A1 · Oct 5, 2017